Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.

MLA

Phillips, Richard O., et al. “Rifampicin and Clarithromycin (Extended Release) versus Rifampicin and Streptomycin for Limited Buruli Ulcer Lesions: A Randomised, Open-Label, Non-Inferiority Phase 3 Trial.” Lancet (London, England), vol. 395, no. 10232, Apr. 2020, pp. 1259–67. EBSCOhost, https://doi.org/10.1016/S0140-6736(20)30047-7.

APA

Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., … van der Werf, T. S. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. Lancet (London, England), 395(10232), 1259–1267. https://doi.org/10.1016/S0140-6736(20)30047-7

Chicago

Phillips, Richard O, Jérôme Robert, Kabiru Mohamed Abass, William Thompson, Fred Stephen Sarfo, Tuah Wilson, Godfred Sarpong, et al. 2020. “Rifampicin and Clarithromycin (Extended Release) versus Rifampicin and Streptomycin for Limited Buruli Ulcer Lesions: A Randomised, Open-Label, Non-Inferiority Phase 3 Trial.” Lancet (London, England) 395 (10232): 1259–67. doi:10.1016/S0140-6736(20)30047-7.